Biosynthesized Selenium nanoparticles as a new catalyst in the synthesis of quinazoline derivatives in pentacyclic system with docking validation as (TRPV1) inhibitor

In recent years, a lot of benefits of Selenium have been discovered for humans, animals and chemical uses. Nano-Selenium was biosynthesized and characterized by using FTIR, UV/Vis., TEM/SAED, and mapping to ensure their crystallinity. The N-bridged imidazo-quinazoline derivatives were successfully synthesized in pentacyclic nonlinear ortho fused polynuclear by a one-pot reaction of aldehyde, beta-naphthol, and 2-aminobenzoimidazole in the presence of a catalytic amount of aqueous nano-Se as a highly efficient and facile catalyst at 70-80 degrees C. The molecular docking study as TRPV1 inhibitor compared with Rutaecarpine and Evodiamine as reference alkaloids ligands. (C) 2021 Elsevier B.V. All rights reserved.

Automated summary

Selenium has been found to have many benefits for humans, animals, and chemical uses. Nano-Selenium was biosynthesized and characterized as a catalyst in the synthesis of N-bridged imidazo-quinazoline derivatives, showing highly efficient and facile properties. Molecular docking study was conducted to compare TRPV1 inhibitor activity with reference alkaloids ligands.